Not a great start to the week but its early and hopefully we can get some momentum. One potential issue is that we have not really had much M&A to follow up on the TRIL deal that generated excitement in the sector. I do not think we are there yet but at some point if […]
September 1st Biotech Update
I am back, although I am lucky to have power as most of Baton Rouge is still without power (which means without AC when the heat index is over 100 degrees). I have not been able to follow the sector too closely but it looks like we are having a nice little breakout with some […]
August 25th Biotech Update
We lost a little bit of the momentum yesterday but we have had a short strong move and so a little pause is not crazy. Of course a little pause to refresh is different than a move back towards the lower end of the range. Yes, my assumption will remain that we are in that […]
August 23rd Biotech Update
What is happening? Do we actually have M&A that could be more broadly meaningful for the sector? I think we might actually have had one. Obviously we need to see how the sector ultimately reacts to the deal but it is setup as being really good for the sector and not just for one day […]
September 9th Biotech Update
Yesterday could have been worse and it could have been better. It seemed like we were going to get a real nice bounce and perhaps even get to green but it seemed to stall at the end of the day. So when all was said and done it was basically a day that had a […]
March 4th Biotech Update
Who would have thought that a Joe Biden Super Tuesday victory would cure the corona virus? The market is rallying on the election as it seems to put Biden back in as the democrat frontrunner. I suspect that the market would strongly prefer Biden over Sanders as the economy and market actually did pretty well […]
ASH Update: TRIL
Trillium Therapeutics presented interim data from its ongoing Phase 1 trial of the SIRPaFc TTI-621 at ASH this past weekend. These highly anticipated results gave a deeper look into the molecule’s safety and efficacy profile as well as potential mechanism of action. Trillium is at the forefront of a scramble to target the SIRPa-CD47 checkpoint […]
TRIL – A quick update from BloomBurton 2016 conference
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium Therapeutics (TRIL) presented at BloomBurton-2016 Healthcare Investor Conference in Toronto on May 3rd, the same as last year the speaker was TRIL’s Chief Scientific Officer (CSO) Dr. Bob Uger, he took the stand in Hall A (the largest room at the conference) that was full with investors, press […]
TRIL – Preparing For The Next Move Upward
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat” signal to macrophages. High expression of CD47 by tumor cells has been correlated with more aggressive disease and poor survival. SIRPαFc is initially being developed […]
Quick update from TRIL Presentation in Toronto
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium Therapeutics presented at Bloomburton-2015 Healthcare Investor Conference in Toronto on May 5th, the speaker Dr. Rob Uger, TRIL’s Chief Scientific Officer (CSO) was very informative during the presentation, mentioned that TRIL are looking for a combination therapy with other immunological agents such as Approved cancer antibodies, T cell […]
